Pfizer (PFE) Common Equity (2009 - 2026)

Pfizer (PFE) has reported Common Equity for 18 consecutive years, with $85.5 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 3.95% year-over-year to $85.5 billion in Q2 2026; TTM through Jun 2026 was $85.5 billion, a 3.95% decrease from a year earlier, with the FY2025 full-year figure at $86.8 billion, down 1.95% from the prior year.
• Common Equity was $85.5 billion for Q2 2026 at Pfizer, down from $90.4 billion in the prior quarter.
• Over five years, Common Equity peaked at $101.2 billion in Q2 2023 and troughed at $18.7 billion in Q3 2022.
• A 5-year average of $82.9 billion and a median of $89.2 billion in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 75.41% in 2022 and jumped 341.43% in 2024, its largest moves.
• Over 5 years, Common Equity stood at $95.9 billion in 2022, then decreased by 6.91% to $89.3 billion in 2023, then dropped by 0.89% to $88.5 billion in 2024, then decreased by 1.95% to $86.8 billion in 2025, then slipped by 1.48% to $85.5 billion in 2026.
• The last three Common Equity figures came in at $85.5 billion (Q2 2026), $90.4 billion (Q1 2026), and $86.8 billion (Q4 2025), per Business Quant data.